AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 20-A-09-123.02
Refund to the Federal Government $115,712 ($73,892 Federal share) for claims for top 20 multiple-source physician-administered drugs that were…
The recommendation, in the publisher's words
Refund to the Federal Government $115,712 ($73,892 Federal share) for claims for top 20 multiple-source physician-administered drugs that were ineligible for Federal reimbursement
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- July 21, 2020
- Report
- Alaska Claimed Unallowable Federal Reimbursement for Some Medicaid Physician-Administered Drugs (A-09-19-02001) · find it at HHS OIG
- Kind of report
- Audit
- Agency response
- Concur (as recorded by the publisher)
- Closed
- December 11, 2020 (publisher's date)
- Potential savings
- $73,892 (the publisher's figure; not realised savings)
- Publisher topics
- Financial Stewardship, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- Closed, with status “Closed Implemented”. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
5 more, of which 0 are open in the publisher's file.
- Refund to the Federal Government $1,541,303 ($939,361 Federal share) for claims for single-source physician-administered drugs that were ineligible for Federal reimbursement;HHS OIG 20-A-09-123.01 · issued Jul 21, 2020 · closed Dec 11, 2020Closed Implemented
- Work with CMS to determine the unallowable portion of $7,229 ($3,615 Federal share) for claims for other physician-administered drugs that were submitted with invalid NDCs and that may…HHS OIG 20-A-09-123.03 · issued Jul 21, 2020 · closed May 17, 2021Closed Implemented
- Work with CMS to determine whether the remaining $300,266 ($185,066 Federal share) for claims for other physician-administered drugs could have been billed to the manufacturers to receive…HHS OIG 20-A-09-123.04 · issued Jul 21, 2020 · closed May 17, 2021Closed Implemented
- Work with CMS to determine and refund the unallowable portion of Federal reimbursement for physician-administered drugs that were not billed for rebates after December 31, 2017.HHS OIG 20-A-09-123.05 · issued Jul 21, 2020 · closed May 17, 2021Closed Implemented
- Strengthen its internal controls to ensure that it bills manufacturers for rebates for all physician-administered drugs that are eligible for rebates.HHS OIG 20-A-09-123.06 · issued Jul 21, 2020 · closed May 17, 2021Closed Implemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.